arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Verastem, Inc.

VSTM
$6.74 ▲ +0.15 (+2.28%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
31 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Verastem, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF Margin (%). These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $467.1M
Dividend Yield
Revenue Growth 209.1%
Op. Margin None
ROIC -235.0%
FCF / Share $-1.98
Trailing P/E
Price / Book 9.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$30.91M
↑ +209.1%
Net Income Profit after all expenses
$-209.47M
↓ -60.3%
Operating Margin Operating profit as % of sales
-55.8%
↑ +84.3%
FCF / Share Free cash flow per share
$-1.98
↑ +32.4%
Long-Term Debt Long-term obligations
$40.72M
↑ +1.6%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -235.0% is weak on an absolute basis (target > 10%)
  • FCF Margin (%)FCF Margin (%) of -444.8% is weak on an absolute basis (target > 10%)
  • Interest CoverageInterest Coverage of -149.50x is weak on an absolute basis (target > 5x)
  • FCF / Net IncomeFCF / Net Income of 0.66x is weak on an absolute basis (target > 1x)

Health Breakdown

Profitability
18
Financial Health
18
Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 62 quarters